Australia Markets closed

GlaxoSmithKline plc (GSK)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
34.91+0.63 (+1.84%)
At close: 4:00PM EST

34.99 +0.08 (0.23%)
After hours: 7:01PM EST

Full screen
Trade prices are not sourced from all markets
Previous close34.28
Open34.36
Bid34.85 x 1400
Ask34.92 x 2900
Day's range34.33 - 34.97
52-week range31.43 - 43.18
Volume6,443,186
Avg. volume5,611,600
Market cap87.342B
Beta (5Y monthly)0.35
PE ratio (TTM)35.19
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield2.11 (6.15%)
Ex-dividend date18 Feb 2021
1y target estN/A
  • Motley Fool

    Vir Biotechnology and GlaxoSmithKline Expand Their COVID Partnership to Flu

    Last year, Vir Biotechnology (NASDAQ: VIR) and GlaxoSmithKline (NYSE: GSK) partnered up to develop Vir's coronavirus antibody treatment. The London-based pharma must have liked what it saw in Vir, because GlaxoSmithKline recently signed on to develop more drugs developed by Vir. In this video from Motley Fool Live, recorded on Feb. 22, Fool.com contributors Brian Orelli and Keith Speights discuss the deal, which covers treatments and preventions for the flu and other viral infections, and what it means for Vir's future.

  • Motley Fool

    Will Sanofi and GlaxoSmithKline Be Too Late to the Party With Their COVID Vaccine?

    Johnson & Johnson (NYSE: JNJ) recently won U.S. Emergency Use Authorization (EUA) for its vaccine. In this Motley Fool Live video, recorded on Feb. 24, Fool.com contributors Keith Speights and Brian Orelli discuss whether or not Sanofi and GlaxoSmithKline might be too late to the party.

  • New Strong Sell Stocks for March 3rd
    Zacks

    New Strong Sell Stocks for March 3rd

    Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today